Sermorelin vs CJC-1295 | Buy Sermorelin | Buy CJC-1295

lotilabs blog banner

Sermorelin vs CJC-1295 | Buy Sermorelin | Buy CJC-1295

Please Read our Disclaimer

Growth Hormone-Releasing Hormone (GHRH) plays a very important role in many species. Produced in the hypothalamus region of the brain, it is transported to the anterior pituitary gland where it stimulates the release of Growth Hormone (GH).

Growth Hormone (GH) is then responsible for the stimulation of growth, cell regeneration, cell reproduction, and other biological processes in many species. Since its discovery, a number of Growth Hormone-Releasing Hormone (GHRH) analogues have been naturally and synthetically isolated and produced to mimic its function.

Two of these analogues are Sermorelin and CJC-1295 with DAC. Although they are essentially analogues of the same peptide, they still have functions and characteristics that are unique with each other.

What is Sermorelin?

Sermorelin is a synthetic analogue and is the shortest functional fragment of GHRH. It is only composed of 29 amino acid chain with a molecular mass of 3357 g/mol and a molecular formula of C149H246N44O42S.

What is CJC-1295 with DAC?

CJC-1295 with DAC on the other hand is also a synthetic analogue of GHRH composed of 30 amino acid chain. It has a molecular weight of 3368 g/mol and a molecular formula of C152H252N44O42.

DAC stands for Drug Affinity Complex which in animal tests and experiments showed to prolong the half-life of CJC-1295.

Pharmacokinetics

Mechanism of Action. Both Sermorelin and CJC-1295 with DAC works by stimulating the release of Growth Hormone by the pituitary gland. Sermorelin specifically stimulates the gene transcription of the pituitary mRNA and activates the anterior pituitary receptors for GHRH resulting to increased GH secretion.

Half Life. CJC-1295 with DAC has a longer half-life than Sermorelin. Studies puts CJC-1295’s half-life at around 6-8 days. The addition of Drug Affinity Complex and its ability to bind to serum albumin and avoid enzyme degradation is responsible for this prolonged half-life.

On the other hand, Sermorelin is rapidly cleared from the plasma due to degradation thus a lower half-life. Intravenous injections in rats shows that Sermorelin has only a half-life of around 6.2 minutes.

Potency. Despite having a lower half-life, Sermorelin is more potent than CJC-1295. A study conducted on rat pituitary cell cultures confirmed that it is capable of stimulating GH release at concentration as low as 0.4 X 10− 15 M.

Effects of Sermorelin and CJC-1295 with DAC

Having similar mechanism of actions, it is expected that both of these peptides will have similar effects. Some of these effects includes but not limited to the following:

Augmented Protein Synthesis. One of the main actions of Growth Hormone is protein synthesis. Increasing its release means that increasing the rate at which protein are synthesized. This led to increased muscle mass and size in animal test subjects given with these peptides.

Better Fat Metabolism. Both peptides increase the efficiency at which adipose tissues or fats are metabolized. This increase in efficiency also means that fats are burned off at a faster and more proficient manner.

Stronger Bones. Another effect of the increase in GH release is the increase in bone matter growth. Rats given with CJC-1295 have shown to have higher mineral matter per square centimeter in their bones than the control group which received none.

Bottomline

Despite having almost identical chemical structure and functional properties, Sermorelin and CJC-1295 still have differences especially when it comes to their pharmacokinetic properties like half-life, potency, and mechanism of action.

However, their effects still boils down to the increase in the release of growth hormone by the anterior pituitary gland. Choosing between the two will be a matter of what your study is about and what specific parameters you want to measure.

References

  1. Walker, R. (2006). Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?. Clinical Interventions in Aging, 1(4):307-308.
  2. Walker, R., Eichler, D., & Bercu, B. (1994). Inadequate pituitary stimulation: a possible cause of growth hormone insufficiency and hyperprolactinemia in rats. Endocrine Journal, 2(7): 633-638.
  3. Furman, B. (2017). Sermorelin. Reference Module in Biomedical Sciences.

Teichman, S. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology Metabolism, 91(3):799-805.

Share this post

Disclaimer-lotilabs-banner